LEXARIA BIOSCIENCE CORP (LEXX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$14.15+14.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LEXX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Execute a 1-for-15 reverse stock split to increase share price and regain compliance with Nasdaq's $1.00 minimum bid price rule.
Newly stated in 2026-Q3. Management announced a 1-for-15 reverse stock split effective August 3, 2026, aiming to regain Nasdaq compliance with the $1.00 minimum bid price rule. There is no financial improvement in revenue or income yet, with revenue at $0 and net loss continuing in 2026-Q3. The priority is newly stated and the company is initiating the compliance action.
“CEO: 'The Reverse Split is a critical step towards our continued listing on Nasdaq... to regain compliance with the Nasdaq minimum $1.00 bid price per share requirement.'”
Continue development and commercialization efforts for the patented DehydraTECH drug delivery platform to improve drug absorption and delivery.
Newly stated in 2026-Q3. Management emphasized advancing the DehydraTECH drug delivery platform as a key growth initiative. Financials show no revenue growth with $0 revenue in 2026-Q3 and ongoing net losses, indicating early-stage development with limited current financial impact.
“Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces DehydraTECH technology advances.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Over the trailing year it converted 0.97x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
16 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.